Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.
about
The human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agentsLevofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.Current pharmacotherapy of pneumococcal meningitis.New therapies and vaccines for bacterial meningitis.The management of bacterial meningitis in children.New therapies for pneumococcal meningitis.Bacterial meningitis: new therapeutic approaches.Bacterial meningitis: an update of new treatment options.Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitisGentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the rabbit meningitis modelGemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin.Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone.Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.
P2860
Q28482276-F506311E-88FB-40AD-830B-951E52AABF2DQ34057612-83855514-6BA9-4797-B98D-553296882A61Q34519236-CBDD6D9E-E80B-4A8A-BC2F-7CEA0868D135Q34768547-9806F1DB-60A2-4C8E-85F2-FD285DB78E30Q35183724-12C3017B-CC60-4983-934A-3ABB452986EBQ35753477-5A63B531-0D9A-4AFC-B6EA-6872959D22A7Q38145360-E343F56A-89B7-4A69-A7EA-AE291B17C8CEQ38570487-70D76C4F-9C76-4440-AAFE-E96E4A6093CDQ39650881-457BCF5D-C27C-4DE9-A55C-E1F1C2206840Q39651068-3EDFA9A9-6A34-4AAC-B3CF-477CA79C47CDQ39651550-AFEAB7A1-E9E4-47AC-BE6D-D26D72A7D675Q39730638-D88E7A5C-9E6C-4ECA-98F1-0E8B1A9EE591Q39743417-86CE0DC3-EDC3-44F0-A0D9-B84DD0A8F792Q39755415-90AD1250-1C28-4674-B8F6-B3AF94F7CC9FQ39792641-97063305-B905-4BAF-BAF7-FE75806D9150
P2860
Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Synergy between trovafloxacin ...... meningitis model and in vitro.
@en
Synergy between trovafloxacin ...... meningitis model and in vitro.
@nl
type
label
Synergy between trovafloxacin ...... meningitis model and in vitro.
@en
Synergy between trovafloxacin ...... meningitis model and in vitro.
@nl
prefLabel
Synergy between trovafloxacin ...... meningitis model and in vitro.
@en
Synergy between trovafloxacin ...... meningitis model and in vitro.
@nl
P2093
P2860
P1476
Synergy between trovafloxacin ...... meningitis model and in vitro.
@en
P2093
M Cottagnoud
M G Täuber
P Cottagnoud
P2860
P304
P356
10.1128/AAC.44.8.2179-2181.2000
P407
P577
2000-08-01T00:00:00Z